Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 3/20 | 0.82 |
| ▸ | HINT1 | P49773 | 1/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.58 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.56 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652603 | 1.00 | HLCS (0.82) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14204782 | 1.00 | HLCS (0.82) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14230061 | 1.00 | HLCS (0.82) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14204795 | 0.97 | HLCS (0.79) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14230477 | 0.97 | HLCS (0.79) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14230472 | 0.97 | HLCS (0.79) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14204798 | 0.97 | HLCS (0.79) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14230032 | 0.95 | HLCS (0.74) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14204790 | 0.95 | HLCS (0.74) | HLCSHINT1P2RY1P2RY2SRC | |
| SCHEMBL14230316 | 0.92 | HLCS (0.71) | HLCSHINT1P2RY1P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025121411-A1 | ALTERED PROXIMITY-DEPENDENT MODIFICATION ENZYME | 株式会社セルフリーサイエンス | 2025-06-12 | — | — | WO | disclosed |
| EP-4533102-A2 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | The Broad Institute, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250084453-A1 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | THE BROAD INSTITUTE, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2025044353-A1 | ADENO-ASSOCIATED VIRUS ENGINEERED WITH TARGETING GENE EDITING ENZYME AND PHARMACEUTICAL COMPOSITION THEREOF | 北京昌平实验室 | 2025-03-06 | — | — | WO | disclosed |
| US-20240125806-A1 | PHOSPHATIDYLSERINE BINDING AGENTS FOR THE DETECTION AND DEPLETION OF PHOSPHATIDYLSERINE POSITIVE CELLS | BioLegend, Inc. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4347860-A1 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | Monte Rosa Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4326307-A1 | PHOSPHATIDYLSERINE BINDING AGENTS FOR THE DETECTION AND DEPLETION OF PHOSPHATIDYLSERINE POSITIVE CELLS | Biolegend, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023235313-A2 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | THE BROAD INSTITUTE, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-114149980-B | Novel protein biotin ligase and proximity marking system PhastID based on same | 中山大学 | 2023-10-13 | — | — | CN | disclosed |
| US-11542549-B2 | Labeled enzyme compositions, methods and systems | Life Technologies Corporation (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022256623-A1 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | MONTE ROSA THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022225796-A1 | PHOSPHATIDYLSERINE BINDING AGENTS FOR THE DETECTION AND DEPLETION OF PHOSPHATIDYLSERINE POSITIVE CELLS | BioLegend, Inc. (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-114728970-A | Optical proximity analysis of protein-protein interactions in cells | 芝加哥大学 | 2022-07-08 | — | — | CN | disclosed |
| CN-114149980-A | Novel protein biotin ligase and proximity labeling system PhastID based on same | 中山大学 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542549-B2 | Labeled enzyme compositions, methods and systems | RNGTT, DNTT, POLB | HLCS 104/4885HINT1 673/4885P2RY1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.